Donald Bobo, Jr. Sells 11,340 Shares of Edwards Lifesciences (NYSE:EW) Stock

Edwards Lifesciences Corporation (NYSE:EW) VP Donald Bobo, Jr. sold 11,340 shares of the stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $85.93, for a total transaction of $974,446.20. Following the transaction, the vice president owned 21,266 shares in the company, valued at approximately $1,827,387.38. This trade represents a 34.78% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Edwards Lifesciences Stock Up 0.9%

NYSE EW traded up $0.80 during trading on Monday, hitting $87.27. 3,749,377 shares of the company traded hands, compared to its average volume of 4,519,282. The company has a current ratio of 3.72, a quick ratio of 3.09 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $50.69 billion, a P/E ratio of 47.69, a PEG ratio of 2.26 and a beta of 0.94. The business has a fifty day simple moving average of $82.74 and a 200 day simple moving average of $81.27. Edwards Lifesciences Corporation has a 12 month low of $65.94 and a 12 month high of $87.89.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Tuesday, February 10th. The medical research company reported $0.58 EPS for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). The firm had revenue of $1.57 billion during the quarter, compared to the consensus estimate of $1.54 billion. Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The company’s revenue for the quarter was up 13.3% compared to the same quarter last year. During the same period in the prior year, the business earned $0.59 EPS. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. As a group, sell-side analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Institutional Investors Weigh In On Edwards Lifesciences

Several institutional investors and hedge funds have recently made changes to their positions in the company. Norges Bank acquired a new stake in shares of Edwards Lifesciences during the 4th quarter worth about $803,686,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its stake in shares of Edwards Lifesciences by 111.2% in the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 9,129,357 shares of the medical research company’s stock valued at $714,006,000 after acquiring an additional 4,805,819 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Edwards Lifesciences by 278.3% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock worth $434,318,000 after acquiring an additional 4,108,270 shares in the last quarter. Marshall Wace LLP boosted its holdings in shares of Edwards Lifesciences by 127.5% in the 2nd quarter. Marshall Wace LLP now owns 6,895,579 shares of the medical research company’s stock worth $539,303,000 after acquiring an additional 3,864,908 shares in the last quarter. Finally, Viking Global Investors LP bought a new stake in Edwards Lifesciences during the 3rd quarter worth approximately $238,688,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a report on Wednesday, January 21st. TD Cowen raised Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Friday, January 9th. The Goldman Sachs Group reiterated a “buy” rating and issued a $95.00 price objective (down from $108.00) on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. Sanford C. Bernstein restated a “market perform” rating and set a $90.00 price objective on shares of Edwards Lifesciences in a research report on Monday, November 3rd. Finally, UBS Group restated a “neutral” rating and issued a $94.00 target price on shares of Edwards Lifesciences in a research note on Wednesday, February 4th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $96.14.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.